Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD

Contributed by: Business Wire

Images

Business Wire associated0
Business Wire embedded0

Tags

Biotechnology
Mental Health
Health
Pharmaceutical
Clinical Trials
Benta

More Like This

(Photo: Business Wire)

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

PR Newswire associated0

Lykos Therapeutics Announces Completion of European Phase 2 Study for MDMA-Assisted Therapy for PTSD

(Photo: Business Wire)

ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a Clinical Trial Evaluating Nantheia™ ATL5 for Smoking Cessation

ANANDA PHARMA LTD ("Ananda" or the "Company") : MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis

Business Wire logo

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Business Wire logo

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder